Table of Contents

company-logo

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

Eyenovia Dividend Announcement

• Eyenovia does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Eyenovia dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Eyenovia Dividend History

Eyenovia Dividend Yield

Eyenovia current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Eyenovia stock? Use our calculator to estimate your expected dividend yield:

Eyenovia Financial Ratios

P/E ratio-0.66
PEG ratio0.02
P/B ratio-10.41
ROE-615.55%
Payout ratio0.00%
Current ratio0.43
Quick ratio0.24
Cash Ratio0.15

Eyenovia Dividend FAQ

Does Eyenovia stock pay dividends?
Eyenovia does not currently pay dividends to its shareholders.
Has Eyenovia ever paid a dividend?
No, Eyenovia has no a history of paying dividends to its shareholders. Eyenovia is not known for its dividend payments.
Why doesn't Eyenovia pay dividends?
There are several potential reasons why Eyenovia would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Eyenovia ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Eyenovia has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Eyenovia a dividend aristocrat?
Eyenovia is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Eyenovia a dividend king?
Eyenovia is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Eyenovia a dividend stock?
No, Eyenovia is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Eyenovia stocks?
To buy Eyenovia you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Eyenovia stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.